About the Company
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MCRB News
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call Transcript March 5, 2024 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.32, ...
Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023
Cash Runway: Year-end cash balance expected to support operations into Q4 2024.
Seres Therapeutics (MCRB) Gets a Buy from TD Cowen
TD Cowen analyst Joseph Thome maintained a Buy rating on Seres Therapeutics (MCRB – Research Report) yesterday. The company’s ...
Seres Therapeutics Stock (NASDAQ:MCRB), Quotes and News Summary
Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial ...
Seres Therapeutics Appoints Marella Thorell As New CFO Following Retirement Of David Arkowitz
(RTTNews) - Seres Therapeutics, Inc. (MCRB), a microbiome therapeutics company, Monday said it named Marella Thorell as its Chief Financial Officer, effective March 25, following the retirement of ...
Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial Officer (CFO), as of ...
Seres Therapeutics GAAP EPS of -$0.89 beats by $0.10, revenue of $126.33M beats by $0.23M
Seres Therapeutics press release (NASDAQ:MCRB): FY GAAP EPS of -$0.89 beats by $0.10. Revenue of $126.33M (+1671.8% Y/Y) beats by $0.23M. As of December 31, 2023, Seres had $128.0 million in cash, ...
Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript
My name is Abby, and will be your conference operator today. At this time, I would like to welcome everyone to the Seres Therapeutics Fourth Quarter 2023 Earnings Conference Call. Today's ...
Seres Therapeutics Inc (MCRB)
(Reuters) -The U.S. health regulator on Wednesday approved Seres Therapeutics (NASDAQ:MCRB) Inc's pill for treating a type of bacterial infection, giving an easier and ...
Seres Therapeutics Inc (MCRB)
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are ...
Loading the latest forecasts...